June 11 (Reuters) - Novavax's (NVAX.O), opens new tab experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, ...
Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates demonstrated a robust immune response in an initial cohort of a late-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results